CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.

Bertrand F. Tombal,Daniel Castellano,Gero Kramer,Jean-Christophe Eymard,Johann S. de Bono,Cora N. Sternberg,Karim Fizazi,Christian Wülfing,Aristotelis Bamias,Joan Carles,Roberto Iacovelli,Bohuslav Melichar,Ásgerður Sverrisdóttir,Christine Theodore,Susan Feyerabend,Carole Helissey,Elizabeth M. Poole,Ayse Ozatilgan,Christine Geffriaud-Ricouard,Ronald de Wit

CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.

2020

5569Background: The CARD trial (NCT02485691) compared cabazitaxel vs. an androgen receptor targeted agent (ART; abiraterone/enzalutamide) in mCRPC previously treated with docetaxel and the alternat...

Keywords:

Abiraterone
Enzalutamide
Oncology
overall survival
Cabazitaxel
Internal medicine
Prostate cancer
Pathology
castration resistant
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations